Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)

A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.

Also Known As:

Networked: 1586 relevant articles (130 outcomes, 211 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Graft vs Host Disease (Graft-Versus-Host Disease)
2.	Neoplasms (Cancer)
3.	Autoimmune Diseases (Autoimmune Disease)
4.	Mycosis Fungoides
5.	Non-Hodgkin Lymphoma (Lymphosarcoma)

Experts

1.	Duvic, Madeleine: 60 articles (11/2015 - 01/2002)
2.	Rook, Alain H: 39 articles (10/2015 - 01/2002)
3.	Dummer, Reinhard: 20 articles (08/2013 - 03/2002)
4.	Wasik, Mariusz A: 19 articles (08/2015 - 11/2002)
5.	Woetmann, Anders: 18 articles (08/2015 - 11/2002)
6.	Kupper, Thomas S: 17 articles (07/2015 - 12/2002)
7.	Kim, Youn H: 16 articles (10/2015 - 03/2002)
8.	Kuzel, Timothy M: 16 articles (02/2014 - 03/2002)
9.	Kim, Ellen J: 15 articles (10/2015 - 07/2003)
10.	Geisler, Carsten: 15 articles (08/2015 - 02/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Cutaneous T-Cell Lymphoma:

1.	bexarotene (LGD1069)FDA Link 04/01/2004 - "Since bexarotene has little bone marrow toxicity, it is an excellent candidate for combination therapy with other modalities useful in the treatment of cutaneous T-cell lymphoma. " 06/01/2004 - "Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene." 08/01/2006 - "Bexarotene is an oral retinoid therapy that is effective for the treatment of early and advanced-stage cutaneous T-cell lymphoma (CTCL) in patients who have failed on other therapies. " 05/01/2001 - "Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results." 10/01/2003 - "In order to evaluate the efficacy of bexarotene in cutaneous T-cell lymphomas, a pilot trial was initiated. "
2.	Methoxsalen (Oxsoralen)FDA Link 01/01/1991 - "Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen (8-MOP) and ultraviolet light, a procedure known as PUVA, has been found to be useful in the management of systemically disseminated cutaneous T-cell lymphoma (CTCL). " 09/01/2001 - "Photoactivational cytokine-modulatory action of 8-methoxypsoralen plus ultraviolet A in lymphocytes, monocytes, and cutaneous T cell lymphoma cells." 07/01/1989 - "Methoxsalen and extracorporeal photoactivation in the treatment of cutaneous T-cell lymphoma." 02/01/2000 - "Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing agent 8-methoxypsoralen and ultraviolet A radiation has been shown to be effective in treatment of selected T-cell mediated diseases, including cutaneous T-cell lymphoma and rejection after organ transplantation. " 11/01/1998 - "Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing compound 8-methoxypsoralen and ultraviolet A radiation has been shown to be effective in the treatment of several T-cell-mediated diseases, including cutaneous T-cell lymphoma and rejection after organ transplantation. "
3.	denileukin diftitox (Ontak)FDA Link 01/01/2013 - "In a placebo-controlled study, denileukin diftitox (DD) was effective against cutaneous T-cell lymphoma (CTCL) expressing CD25. " 03/01/2013 - "This open-label phase III trial, a companion to an earlier placebo-controlled trial, evaluated safety and efficacy of denileukin diftitox (DD) in patients with cutaneous T-cell lymphoma (CTCL) who relapsed after responding to DD primary treatment in the earlier trial. " 08/01/2013 - "Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies." 04/10/2010 - "Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma." 01/15/2001 - "The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics of denileukin diftitox (DAB389IL-2, Ontak [Ligand Pharmaceuticals Inc, San Diego, CA]) in patients with stage Ib to IVa cutaneous T-cell lymphoma (CTCL) who have previously received other therapeutic interventions. "
4.	Interferon-alpha (Interferon Alfa)FDA Link 01/01/1995 - "Interferon alpha was found to be most effective in cutaneous T cell lymphoma with 40%-60% overall responses. " 03/01/1999 - "Although interferon-alfa (IFN-alpha) has proved effective in treating epidermotropic cutaneous T-cell lymphoma (ECTL), few studies have considered the follow-up of treated patients and whether complete remission was maintained. " 10/01/2001 - "[Granulomatous slack skin: partial remission following intralesional administration of interferon-alpha and PUVA]." 07/01/2010 - "Gene expression profiling of primary cutaneous T cell lymphomas highlighted the importance of abnormal methylation patterns, suggested a pivotal role for JUNB/AP-1, and defined a predictive model for response to interferon-alpha. " 09/01/2005 - "[Interferon alpha in the treatment of cutaneous T-cell lymphoma]."
5.	alemtuzumab (Campath)FDA Link 10/01/2003 - "We undertook a phase II study to evaluate the safety, tolerability and efficacy of alemtuzumab in patients with relapsed or refractory advanced stage cutaneous T-cell lymphoma. " 01/01/2006 - "Recently it has been demonstrated in a number of clinical trials that alemtuzumab has clinical activity in mature T-cell diseases such as T-prolymphocytic leukaemia and cutaneous T-cell lymphoma, inducing responses in up to two thirds of heavily pre-treated relapsed/refractory patients. " 03/18/2015 - "In patients with cutaneous T cell lymphoma, malignant TCM and TMM induced distinct inflammatory skin lesions, and TMM were depleted more slowly from skin after alemtuzumab, suggesting that TMM may recirculate more slowly. " 03/01/2014 - "Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas." 05/01/2012 - "Alemtuzumab may belong to the current standard of care for nodal and cutaneous T-cell lymphomas."
6.	InterferonsIBA 01/01/1990 - "23 newly diagnosed patients affected by cutaneous T-cell lymphoma were treated with sub-cutaneous interferon alpha-2a to evaluate the therapeutic efficacy and the toxicity of this agent. " 08/01/1993 - "In this report we have reviewed studies on the clinical effect of the interferon (IFN) treatment of 304 patients suffering from cutaneous T-cell lymphoma (CTCL). " 01/01/1989 - "In this study we treated 6 patients with epidermotropic cutaneous T cell lymphoma (CTCL) with intermediate doses of recombinant alpha 2a interferon (18-100 x 10(6) IU/week) for 2-6 months. " 10/01/2015 - "By harnessing these immunomodulatory functions, synthetic interferons have shown efficacy in combating various diseases including cutaneous T-cell lymphoma. " 10/01/2015 - "The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma."
7.	Ficusin (Psoralen)IBA 03/01/2005 - "Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy." 12/01/2005 - "Psoralen ultraviolet A (PUVA) is a widely used first-line therapy for treatment of early cutaneous T-cell lymphoma. " 11/01/1985 - "A new psoralen plus UVA therapy has been developed in which the 8-MOP-containing blood of cutaneous T cell lymphoma (CTCL) patients is irradiated with UVA light extracorporeally (i.e., extracorporeal photopheresis). " 04/15/2008 - "Psoralen and its derivatives are widely applied for the clinical treatment of several skin diseases and cutaneous T cell lymphoma, and they are also commonly used as model compounds for the study of ICL. " 07/01/2011 - "Psoralen plus ultraviolet A light may be associated with clearing of peripheral blood disease in advanced cutaneous T-cell lymphoma."
8.	vorinostat (suberoylanilide hydroxamic acid)FDA Link 05/15/2015 - "Subsequent studies led to the development of oral vorinostat and the regulatory approval of vorinostat for cutaneous T-cell lymphomas, which opened the door for the next generation of inhibitors." 01/01/2012 - "This review introduces the background and mechanism of action of vorinostat and describes the results of clinical trials using vorinostat, both as a single agent and in combination with other anticancer agents, against cutaneous T-cell lymphoma and other malignancies." 10/14/2010 - "Suberoylanilide hydroxamic acid (SAHA) has been approved as a drug to treat cutaneous T cell lymphoma, and the combination of HDACi and other agents have been actively tested in many clinical trials. " 08/08/2009 - "Clinical trials using these agents are now underway, with Vorinostat (suberoylanilide hydroxamic acid) having been approved by the FDA for treating cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent or recurrent disease. " 11/01/2008 - "FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial."
9.	Histone Deacetylase InhibitorsIBA 10/01/2009 - "In clinical trials, HDAC inhibitors have demonstrated promising antitumour activity as monotherapy in cutaneous T-cell lymphoma and other haematological malignancies. " 11/15/2015 - "Hdac3 is a key target for Hdac inhibitors that are efficacious in cutaneous T cell lymphoma. " 10/01/2015 - "Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma." 09/01/2013 - "HDAC-inhibitors (HDACis) are well tolerated in patients and have been approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL). " 01/01/2013 - "In fact, two histone deacetylase inhibitors (HDIs), SAHA and Depsipeptide, are FDA approved for single-agent treatment of refractory cutaneous T cell lymphoma (CTCL). "
10.	romidepsin (FK228)FDA Link 10/10/2010 - "The primary objective of this study was to confirm the efficacy of romidepsin in patients with treatment refractory cutaneous T-cell lymphoma (CTCL). " 12/01/2013 - "Based on two large Phase II studies, the US FDA approved intravenous romidepsin for patients with relapsed/refractory cutaneous T-cell lymphomas. " 10/01/2012 - "Phase 1 and 2 trials evaluating the efficacy and safety of romidepsin were reviewed with a specific focus on its use in cutaneous T-cell lymphoma. " 10/10/2010 - "Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma." 10/01/2015 - "Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma."

Therapies and Procedures

1.	Photopheresis 10/01/2002 - "Since photopheresis, a treatment that induces an anticlonotypic immune response, has proven to be effective in both cutaneous T cell lymphomas with circulating clonal T cells and in cGVHD, we have searched for circulating clonal T cell populations in patients with cGVHD, and determined whether T cell clonality in the blood is associated with therapeutic response. " 01/01/2014 - "After the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma was published in 1983 with its subsequent recognition by the FDA for its refractory forms, the technology has shown significant promise in the treatment of other severe and refractory conditions in a multi-disciplinary setting. " 06/01/2004 - "Extracorporeal photochemotherapy (ECP), considered as an effective treatment for patients with erythrodermic cutaneous T-cell lymphoma (CTCL), has recently been used successfully in the treatment of GvHD. " 10/01/1996 - "Photopheresis appears to be effective for selected patients with erythrodermic cutaneous T-cell lymphoma, although we did not achieve as high a remission rate as previously reported by others." 07/01/2015 - "Extracorporeal photopheresis (ECP) alone or in combination therapy is effective for treatment of leukemic cutaneous T-cell lymphoma (L-CTCL), but its mechanism(s) of action remain unclear. "
2.	Drug Therapy (Chemotherapy) 03/01/1989 - "Thus, in our experience, a continuous remission lasting 8 or more years provides evidence that cutaneous T cell lymphoma can be eradicated by aggressive topical chemotherapy. " 08/15/2014 - "Two patients with cutaneous T-cell lymphomas had not previously received chemotherapy. " 08/01/2013 - "Recent evidence showed that overexpressed BCL11B conferred chemoresistance to malignant T cells and that inhibiting BCL11B led to increased apoptosis, suggesting its potential pathogenic relevance in cutaneous T-cell lymphomas (CTCL), which were characterized by the resistance to chemotherapy-induced apoptosis. " 08/01/2013 - "Less can be more: the impact of chemotherapy on cutaneous T-cell lymphomas." 01/01/2012 - "Advanced cutaneous T-cell lymphoma (CTCL) is resistant to chemotherapy and presents a major area of medical need. "
3.	Photochemotherapy (Photodynamic Therapy) 11/01/2015 - "Epigenetically Enhanced Photodynamic Therapy (ePDT) is Superior to Conventional Photodynamic Therapy for Inducing Apoptosis in Cutaneous T-Cell Lymphoma." 05/01/2008 - "Monitoring Pc 4 photodynamic therapy in clinical trials of cutaneous T-cell lymphoma using noninvasive spectroscopy." 10/01/2006 - "Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma." 03/01/2004 - "We, therefore, suggest that photodynamic therapy can be a useful additional treatment modality for patients with therapy-resistant lesions of cutaneous T-cell lymphoma." 03/01/2004 - "We treated 4 patients with different cutaneous T-cell lymphomas with photodynamic therapy. "
4.	Transplants (Transplant) 02/01/2014 - "We report on a patient who developed donor-derived cutaneous T-cell lymphoma (CTCL) 4 years after successful treatment of chronic myeloid leukaemia with an allogeneic bone marrow transplant. " 11/01/2013 - "Biopsy results support an etiological role for HTLV-1 in these cases of primary cutaneous T-cell lymphoma after solid organ transplant. " 10/01/2005 - "Post-transplant cutaneous T-cell lymphomas." 01/01/2003 - "Post-transplant cutaneous T-cell lymphomas are extremely rare. " 01/01/2009 - "We describe here a rare primary cutaneous T-cell lymphoma CD30+ arising in a heart transplant patient who had a nodule on the right leg, several years after heart transplantation. "
5.	Phototherapy (Light Therapy) 07/01/2010 - "Phototherapy is well-recognized as effective therapy in early stage cutaneous T-cell lymphoma (patch and plaque), often resulting in complete clearance of clinical disease and subsequent remission. " 06/01/2010 - "Our results confirm that phototherapy is a safe, effective and well-tolerated, first-line therapy in patients with early-stage cutaneous T-cell lymphoma, with prolonged disease-free remissions being achieved. " 01/01/2014 - "We conclude that narrowband-UVB phototherapy is safe and effective for the treatment of early stage cutaneous T-cell lymphoma in darker-skinned patients. " 07/01/2010 - "Herein, the authors review the literature regarding the role of maintenance phototherapy in cutaneous T-cell lymphoma (CTCL) and its success in prolonging clinical remission and disease-free survival in CTCL." 07/01/2010 - "The role of maintenance phototherapy in cutaneous T-cell lymphoma."